Premium
99m Tc Labeled Biotin Conjugate in a Tumor “Pretargeting” Approach with Monoclonal Antibodies
Author(s) -
Koch Peter,
Mäcke Helmut Robert
Publication year - 1992
Publication title -
angewandte chemie international edition in english
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 0570-0833
DOI - 10.1002/anie.199215071
Subject(s) - pretargeting , avidin , biotin , conjugate , monoclonal antibody , chemistry , in vivo , monoclonal , in vitro , streptavidin , antibody , radioimmunotherapy , biochemistry , medicine , biology , immunology , mathematical analysis , mathematics , microbiology and biotechnology
Very stable in vitro and in vivo , the complex of 99m Tc and the biotin derivative 1 shows, like biotin, a high affinity for the glycoprotein avidin. It was successfully used to diagnose brain tumors when the patients were treated three days previously with an unlabeled conjugate of a tumor‐specific monoclonal antibody and avidin.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom